Genpharmasec Ltd
GENPHARMAGenpharmasec Ltd
GENPHARMA
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 163.48 | 2.81 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.98 | 7.23 | 0.45% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Generic Pharmasec Ltd is an India-based company. The Company is focused on trading and dealing in chemicals.
Peers
Compare with peersAdani Enterprises Ltd
MMTC Ltd
MSTC Ltd
Veritas (India) Ltd
Mercury Ev-Tech Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2023 | FY 2024 | TTM | |||
|---|---|---|---|---|---|---|
| Total Revenue | 25.62 | 31.07 | 29.07 | |||
Raw Materials | 23.18 | 23.40 | 27.61 | |||
| Power & Fuel Cost | 0.00 | 0.00 | ||||
| Employee Cost | 0.54 | 0.76 | ||||
| Selling & Administrative Expenses | 0.95 | 3.36 | ||||
| Operating & Other expenses | 0.58 | 2.84 | ||||
EBITDA | 0.37 | 0.71 | 1.46 | |||
| Depreciation/Amortization | 0.02 | 0.04 | 0.32 | |||
| PBIT | 0.35 | 0.67 | 1.14 | |||
| Interest & Other Items | 0.06 | 0.41 | 0.32 | |||
| PBT | 0.29 | 0.26 | 0.82 | |||
| Taxes & Other Items | -0.84 | 0.38 | -0.29 | |||
| Net Income | 1.13 | -0.12 | 1.11 | |||
| EPS | 0.02 | -0.00 | 0.02 | |||
| DPS | 0.00 | 0.00 | 0.00 | |||
| Payout ratio | 0.00 | 0.00 | 0.00 |
Company Updates
Investor Presentation
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
IndustrialsCommodities Trading
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Genpharmasec Ltd | -1,512.21 | 2.81 | — |
| Adani Enterprises Ltd | 104.03 | 7.63 | 0.04% |
| MMTC Ltd | 71.95 | 8.51 | — |
| MSTC Ltd | 24.56 | 5.64 | 2.17% |
Price Comparison
Compare GENPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 4.29%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Feb 2024
Mar 2024
Jun 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
GENPHARMA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Genpharmasec rose 1866.67% to Rs 0.59 crore in the quarter ended June 2024 as against Rs 0.03 crore during the previous quarter ended June 2023. Sales declined 11.07% to Rs 5.30 crore in the quarter ended June 2024 as against Rs 5.96 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales5.305.96 -11 OPM %4.150.50 - PBDT0.730.08 813 PBT0.730.07 943 NP0.590.03 1867 Powered by Capital Market - Live
Genpharmasec will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Generic Pharmasec reports standalone net loss of Rs 0.61 crore in the September 2021 quarter
Generic Pharmasec Ltd. successfully executes an order from Reliance Group
Generic Pharmasec successfully executes order from Reliance Group
Generic Pharmasec standalone net profit rises 445.65% in the March 2021 quarter
Generic Pharmasec enters into agreement with Abbott Point of Care (APOC)
Generic Pharmasec standalone net profit declines 80.00% in the December 2020 quarter
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 29.98%
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant